ZZVET / SHUTTERSTOCK.COM
The battle between pharmaceutical and generics companies in India is once again in the spotlight, with a decision pending on another compulsory licence. The players this time are Novartis and Cipla, with the former already having drawn first blood. LSIPR investigates.
The last 12 months have brought a lot of change in India. First, a new government, the Bharatiya Janata Party, was voted into office in May 2014 and said straight away it would be focusing on, among other things, intellectual property.
Then, shortly after the election, Nirmala Sitharaman, the new commerce and industry minister, said India would “constructively engage” with the US—a long-term critic of its IP regime—about it.
The US Trade Representative’s annual Special 301 Report had included India on its ‘priority watch list’ (the report assesses US trading partners’ efforts to protect IP, and was released a few weeks before the general election). However, these two developments suggested that fears concerning India’s patent laws, particularly those surrounding pharmaceuticals, might soon be addressed.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Novartis, Cipla, Inidan Patent Office, Onbrez, compulsory licence, Delhi High Court